Advertisement

Management of pulmonary oligometastases by stereotactic body radiotherapy

Abstract

Aims and background. The aim of the study was to evaluate the feasibility, toxicity and effectiveness of active breathing control-guided stereotactic body radiotherapy in the management of pulmonary oligometastases.
Methods and study design. Between June 2010 and June 2012, 20 patients (13 males, 7 females) with 31 pulmonary metastases referred to the Department of Radiation Oncology, Gulhane Military Medical Academy were treated using active breathing control-guided stereotactic body radiotherapy. Response Evaluation Criteria in Solid Tumors and Common Terminology Criteria for Adverse Events were used in the assessment of treatment response and toxicity, respectively.
Results. Assessment of treatment response revealed complete response, partial response, stable disease, and progressive disease in 30%, 25%, 30%, and 15% of the patients, respectively. At a median follow-up of 14 months, local control was 85% and overall survival was 70%, with negligible treatment-related toxicity.
Conclusions. Stereotactic body radiotherapy is safe and effective in the management of pulmonary oligometastases. It offers favorable treatment outcomes as a viable non-invasive therapeutic modality.

Tumori 2014; 100(2): 179 - 183

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.1700/1491.16407

Authors

Hakan Gamsiz, Murat Beyzadeoglu, Omer Sager, Ferrat Dincoglan, Selcuk Demiral, Bora Uysal, Serdar Surenkok, Kaan Oysul, Bahar Dirican

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Gamsiz, Hakan [PubMed] [Google Scholar]
    Department of Radiation Oncology, Gulhane Military Medical Academy, Ankara, Turkey
  • Beyzadeoglu, Murat [PubMed] [Google Scholar]
    Department of Radiation Oncology, Gulhane Military Medical Academy, Ankara, Turkey
  • Sager, Omer [PubMed] [Google Scholar]
    Department of Radiation Oncology, Gulhane Military Medical Academy, Ankara, Turkey
  • Dincoglan, Ferrat [PubMed] [Google Scholar]
    Department of Radiation Oncology, Gulhane Military Medical Academy, Ankara, Turkey
  • Demiral, Selcuk [PubMed] [Google Scholar]
    Department of Radiation Oncology, Gulhane Military Medical Academy, Ankara, Turkey
  • Uysal, Bora [PubMed] [Google Scholar]
    Department of Radiation Oncology, Gulhane Military Medical Academy, Ankara, Turkey
  • Surenkok, Serdar [PubMed] [Google Scholar]
    Department of Radiation Oncology, Gulhane Military Medical Academy, Ankara, Turkey
  • Oysul, Kaan [PubMed] [Google Scholar]
    Department of Radiation Oncology, Gulhane Military Medical Academy, Ankara, Turkey
  • Dirican, Bahar [PubMed] [Google Scholar]
    Department of Radiation Oncology, Gulhane Military Medical Academy, Ankara, Turkey

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.